The independent source for health policy research, polling, and news.
Showing 241 - 260 of 582
The fate of the Affordable Care Act鈥檚 individual insurance marketplaces remains in play as state insurance commissioners take a central role in the debate.
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
Republican senators are warming to the idea of a scaled-back plan that would delete the Affordable Care Act鈥檚 individual and employer mandates but leave the rest of law generally intact. But this approach has caused difficulties in the past.
During another day of fast-moving developments, Senate Republicans signaled their intent to attempt to bring an updated repeal-and-delay bill to the floor for a vote next week.
The failure this week of the U.S. Senate鈥檚 ACA repeal effort was one more twist in the ongoing political drama that has complicated routine rate setting for insurers and state officials.
A key bill provision would likely lower premiums, but coverage would be skimpier with consumers left to figure out the trade-offs.
Congressional Republicans are keen to loosen restrictions set by the federal health law on insurance sold by associations that small employers join.
Similar to the House-passed American Health Care Act, the Senate GOP health bill would change or eliminate more than a dozen taxes that were put in place to help pay for provisions of the Affordable Care Act.
A little-noticed provision of the Senate GOP health plan would unwind an Affordable Care Act provision limiting insurer profits, administrative costs.
The latest Republican plan to revamp the health law reshapes how age and income affect what help consumers get for paying premiums.
The study also found that the largest percentage of medical coverage claims related to opioid abuse and dependence nationally come from older patients 鈥 those ages 51 to 60.
A new law gives Medicaid regulators power to threaten drugmakers with cost-effectiveness scrutiny unless they grant additional rebates.
A look at how and why strategic, star-studded advertising brought a drug for a little-known neurological condition into your home.
Even though the GOP health plan is stalled by intraparty negotiations, some big insurance changes are still in the works.
Spending on consumer advertising by drugmakers has increased 62 percent since 2012.
With Republicans in control of Congress and the White House, HSAs 鈥 a longtime favorite of conservatives 鈥 are likely to get a boost.
鈥淧ortability鈥 will likely be a buzz word in the health law repeal-and-replace debate, but the concept raises a number of complicated policy issues.
As Republicans consider how to bring down costs for younger people, lawmakers may relax or eliminate the restrictions on how much more insurers can charge older consumers.
Republicans hope to expand the use of health savings accounts to encourage consumers to be more judicious in using their coverage. Here鈥檚 an explainer of how they work.
Stay informed by signing up for the Morning Briefing and other emails:
漏 2026 KFF